Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold by CenterBook Partners LP

CenterBook Partners LP cut its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 11.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 350,473 shares of the biotechnology company's stock after selling 44,105 shares during the quarter. CenterBook Partners LP owned 0.28% of Arrowhead Pharmaceuticals worth $6,589,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Raymond James Financial Inc. acquired a new position in shares of Arrowhead Pharmaceuticals during the 4th quarter worth $651,000. ADAR1 Capital Management LLC boosted its holdings in Arrowhead Pharmaceuticals by 10.2% during the fourth quarter. ADAR1 Capital Management LLC now owns 12,900 shares of the biotechnology company's stock worth $243,000 after buying an additional 1,195 shares in the last quarter. Bank of Montreal Can grew its position in Arrowhead Pharmaceuticals by 13.3% during the fourth quarter. Bank of Montreal Can now owns 15,018 shares of the biotechnology company's stock worth $282,000 after buying an additional 1,759 shares during the period. Dynamic Technology Lab Private Ltd purchased a new position in Arrowhead Pharmaceuticals in the fourth quarter valued at about $360,000. Finally, Wells Fargo & Company MN lifted its position in shares of Arrowhead Pharmaceuticals by 43.1% during the 4th quarter. Wells Fargo & Company MN now owns 62,886 shares of the biotechnology company's stock valued at $1,182,000 after acquiring an additional 18,933 shares during the period. Institutional investors and hedge funds own 62.61% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on ARWR shares. B. Riley reaffirmed a "buy" rating and set a $38.00 price objective (down from $51.00) on shares of Arrowhead Pharmaceuticals in a report on Friday, February 14th. HC Wainwright reiterated a "buy" rating and set a $80.00 price target on shares of Arrowhead Pharmaceuticals in a report on Wednesday, February 12th. Chardan Capital reissued a "buy" rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $42.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. Finally, StockNews.com raised Arrowhead Pharmaceuticals to a "sell" rating in a research report on Friday, December 20th. One analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, Arrowhead Pharmaceuticals presently has an average rating of "Hold" and a consensus target price of $41.44.

Insider Activity

In other Arrowhead Pharmaceuticals news, CEO Christopher Richard Anzalone sold 50,800 shares of the firm's stock in a transaction that occurred on Friday, April 11th. The stock was sold at an average price of $11.49, for a total transaction of $583,692.00. Following the completion of the sale, the chief executive officer now owns 3,921,255 shares in the company, valued at $45,055,219.95. This trade represents a 1.28 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last quarter, insiders sold 276,839 shares of company stock worth $4,054,176. 4.30% of the stock is currently owned by corporate insiders.

Arrowhead Pharmaceuticals Trading Up 1.5 %

ARWR traded up $0.18 during trading on Monday, hitting $11.97. 572,396 shares of the company's stock were exchanged, compared to its average volume of 1,406,135. Arrowhead Pharmaceuticals, Inc. has a 1 year low of $9.57 and a 1 year high of $30.41. The stock has a 50 day moving average price of $16.07 and a 200 day moving average price of $18.86. The firm has a market cap of $1.64 billion, a P/E ratio of -2.32 and a beta of 0.99. The company has a current ratio of 6.09, a quick ratio of 6.09 and a debt-to-equity ratio of 7.27.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last announced its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.97). As a group, analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current fiscal year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.